Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation

BMC Genomics

Volumn 11, Issue 1, 2010, Pages

  Riehl, Astrid ^a   Bauer, Tobias ^b   Brors, Benedikt ^b   Busch, Hauke ^b,c   Mark, Regina ^a,e   Németh, Julia ^a   Gebhardt, Christoffer ^e   Bierhaus, Angelika ^e   Nawroth, Peter ^e   Eils, Roland ^b,d   König, Rainer ^b,d   Angel, Peter ^a   Hess, Jochen ^a,e  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; EARLY GROWTH RESPONSE FACTOR; MYC PROTEIN; PHORBOL ESTER; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR TCFAP2; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER PREDICTION; CONTROLLED STUDY; EPIDERMIS CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE REGULATORY NETWORK; KERATINOCYTE; MATHEMATICAL COMPUTING; MOUSE; NONHUMAN; PATHOGENESIS; PROMOTER REGION; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; TRANSCRIPTION INITIATION; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; BIOLOGY; CLUSTER ANALYSIS; DISEASE MODEL; DRUG EFFECT; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; TIME;

MUS;

ANIMALS; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; INFLAMMATION; MICE; MODELS, BIOLOGICAL; PROMOTER REGIONS, GENETIC; RECEPTORS, IMMUNOLOGIC; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS;

EID: 77957255564     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-11-537     Document Type: Article

References (47)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545. 10.1016/S0140-6736(00)04046-0, 11229684.
3. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008, 205:275-285. 10.1084/jem.20070679, 2271015, 18208974.
4. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008, 29:2035-2043. 10.1093/carcin/bgn188, 2556970, 18689872.
5. Riehl A, Nemeth J, Angel P, Hess J. The receptor RAGE: Bridging inflammation and cancer. Cell Commun Signal 2009, 7:12. 10.1186/1478-811X-7-12, 2690588, 19426472.
6. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009, 52:2251-2263. 10.1007/s00125-009-1458-9, 19636529.
7. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002, 54:1615-1625. 10.1016/S0169-409X(02)00160-6, 12453678.
8. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 2007, 7:743-751. 10.2174/156652407783220714, 18331232.
9. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360. 10.1038/35012626, 10830965.
10. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, Bierhaus A, Lotze MT, Zeh HJ. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2009,
11. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007, 7:777-789. 10.2174/156652407783220697, 18331236.
12. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002, 1:1-15. 10.1016/S0047-6374(01)00366-9, 12039445.
13. Lin L. RAGE on the Toll Road?. Cell Mol Immunol 2006, 3:351-358.
14. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008, 11:91-99. 10.1007/s10456-008-9093-5, 18264787.
15. Busch H, Camacho-Trullio D, Rogon Z, Breuhahn K, Angel P, Eils R, Szabowski A. Gene network dynamics controlling keratinocyte migration. Mol Syst Biol 2008, 4:199. 10.1038/msb.2008.36, 2516358, 18594517.
16. DeGregori J, Johnson DG. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr Mol Med 2006, 6:739-748.
17. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009, 9:738-748. 10.1038/nrc2718, 19776743.
18. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001, 50:2792-2808. 10.2337/diabetes.50.12.2792, 11723063.
19. Lv B, Wang H, Tang Y, Fan Z, Xiao X, Chen F. High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost 2009, 102:352-359. 2860734, 19652887.
20. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH. Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J Immunol 2009, 182:5778-5788. 10.4049/jimmunol.0803013, 19380826.
21. Zeng S, Dun H, Ippagunta N, Rosario R, Zhang QY, Lefkowitch J, Yan SF, Schmidt AM, Emond JC. Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury. J Hepatol 2009, 50:929-936. 10.1016/j.jhep.2008.11.022, 19303658.
22. Chang JS, Wendt T, Qu W, Kong L, Zou YS, Schmidt AM, Yan SF. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res 2008, 102:905-913. 10.1161/CIRCRESAHA.107.165308, 18323529.
23. Mookherjee N, Hamill P, Gardy J, Blimkie D, Falsafi R, Chikatamarla A, Arenillas DJ, Doria S, Kollmann TR, Hancock RE. Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Mol Biosyst 2009, 5:483-496. 10.1039/b813787k, 19381363.
24. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997, 272:16498-16506. 10.1074/jbc.272.26.16498, 9195959.
25. Reynolds PR, Kasteler SD, Cosio MG, Sturrock A, Huecksteadt T, Hoidal JR. RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1094-1101. 10.1152/ajplung.00318.2007, 18390831.
26. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005, 24:2810-2826. 10.1038/sj.onc.1208612, 15838517.
27. Polager S, Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol 2008, 18:528-535. 10.1016/j.tcb.2008.08.003, 18805009.
28. Macaluso M, Montanari M, Giordano A. Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes. Oncogene 2006, 25:5263-5267. 10.1038/sj.onc.1209680, 16936746.
29. Stevaux O, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol 2002, 14:684-691. 10.1016/S0955-0674(02)00388-5, 12473340.
30. Huart AS, MacLaine NJ, Meek DW, Hupp TR. CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem 2009, 284:32384-32394. 10.1074/jbc.M109.052647, 19759023.
31. Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005, 24:7238-7247. 10.1038/sj.onc.1208814, 16170383.
32. Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Rokas M, DePinho RA, Livingston DM, Grossman SR. p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 2001, 98:4455-4460. 10.1073/pnas.081061398, 31856, 11274364.
33. Kontaki H, Talianidis I. Lysine methylation regulates E2F1-induced cell death. Mol Cell 2010, 39:152-160. 10.1016/j.molcel.2010.06.006, 20603083.
34. Ivanova IA, D'Souza SJ, Dagnino L. E2F1 stability is regulated by a novel-PKC/p38beta MAP kinase signaling pathway during keratinocyte differentiation. Oncogene 2006, 25:430-437.
35. Ivanova IA, Dagnino L. Activation of p38- and CRM1-dependent nuclear export promotes E2F1 degradation during keratinocyte differentiation. Oncogene 2007, 26:1147-1154. 10.1038/sj.onc.1209894, 16924238.
36. Leitch AE, Haslett C, Rossi AG. Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br J Pharmacol 2009, 158:1004-1016. 10.1111/j.1476-5381.2009.00402.x, 2785523, 19775281.
37. Hallett JM, Leitch AE, Riley NA, Duffin R, Haslett C, Rossi AG. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol Sci 2008, 29:250-257. 10.1016/j.tips.2008.03.002, 18407359.
38. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G, Arnold B. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 2001, 30:36-44. 10.1002/gene.1030, 11353516.
39. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods 2003, 31:265-273. 10.1016/S1046-2023(03)00155-5, 14597310.
40. Smyth GK. Limma: linear models for microarray data 2005, New York: Springer.
41. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc B 1995, 57:289-300.
42. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4:P3. 10.1186/gb-2003-4-5-p3, 12734009.
43. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57. 10.1038/nprot.2008.211, 19131956.
44. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 2005, 33:D54-58. 10.1093/nar/gki031, 539985, 15608257.
45. Rahmann S, Muller T, Vingron M. On the power of profiles for transcription factor binding site detection. Stat Appl Genet Mol Biol 2003, 2:Article7.
46. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008, 9:R150. 10.1186/gb-2008-9-10-r150, 2760877, 18851746.
47. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006, 34:D108-110. 10.1093/nar/gkj143, 1347505, 16381825.